The kidney transplantation therapeutics market is projected to experience significant growth in the coming years, according to a report by Technavio. The market is estimated to expand by USD 643.15 million between 2024 and 2028, with a compound annual growth rate (CAGR) of 4.49%. The rising prevalence of chronic kidney disease (CKD) and renal impairments is a major driver for this growth. CKD affects approximately 8.5%-9.5% of the global adult population, and its incidence is increasing due to factors such as non-communicable diseases, diabetes, hypertension, vascular disease, and glomerulonephritis. CKD in underdeveloped and developing nations is primarily caused by glomerulonephritis and interstitial nephritis, which are associated with a high prevalence of infections.
The kidney transplantation therapeutics market is highly competitive, with companies vying for market share and new entrants entering the market. Major companies in the market rely on positioning, technological advancements, and pricing strategies to maintain their market presence. The report provides a comprehensive list of key companies, their strategies, and the latest developments. Technavio has identified key trends, drivers, and challenges in the market, which can help companies improve their strategies and stay competitive. Additionally, the report includes information on product launches, sustainability, and prospects of leading companies in the market.
The selective cytokine inhibitors segment is expected to exhibit significant growth during the forecast period. These medications inhibit the production and activity of cytokines, which are signaling molecules that facilitate immune response transmission between cells. Kidney transplantation is a critical treatment for end-stage renal disease (ESRD), involving the transfer of a donor kidney to a recipient. Immunosuppressive drugs play a crucial role in preventing graft rejection. HLA matching and post-transplant care are also important for successful kidney transplantation. The market includes companies such as AbbVie Inc., Asahi Kasei Corp., Astellas Pharma Inc., and Novartis AG, among others.
If you want more detailed information or the full report, you can contact Technavio via their website or by email. Technavio is a leading global technology research and advisory company, providing insights to help businesses identify opportunities and develop effective strategies.
